Chương trình khoa học cập nhật công nghệ TAVI tại Bệnh viện 198 -1
The scientific workshop held successfully at 19-8 Hospital, Vietnam.

On May 6, HDN, Relisys, and the Cardiovascular Institute of 19-8 Hospital successfully organized a scientific program focusing on structural heart intervention technologies, attracting active participation and discussion from leading professors, cardiologists, and medical experts.

During the event, TAVI specialist Mrs. Mili Gangrade presented updates on the latest innovations in both Transcatheter Aortic Valve Implantation (TAVI) and Transcatheter Caval Valve Intervention (TricValve) technologies.

Chương trình khoa học cập nhật công nghệ TAVI tại Bệnh viện 198 -2
Representatives and speakers from Relisys Medical Devices introducing the VIENNA transcatheter aortic valve technology.

The VIENNA Aortic Valve SE is a next-generation self-expanding transcatheter biological aortic valve designed for the treatment of severe aortic stenosis in patients considered at risk for open-heart surgery. The system enables replacement of the diseased valve without surgical removal and is delivered via the femoral artery using a minimally invasive approach.

One of the most notable advancements of the new-generation SE platform is its proprietary dry bovine pericardial tissue technology with a pre-mounted valve design, significantly reducing preparation time while optimizing procedural workflow efficiency. Currently, this technology is uniquely available worldwide and in Vietnam, with exclusive distribution rights held by HDN through its partnership with Relisys.

Chương trình khoa học cập nhật công nghệ TAVI tại bệnh viện 198 -3
Specialists, professors, and physicians at the Cardiovascular Institute of 19-8 Hospital attentively listening and engaging during the scientific session on advanced structural heart intervention technologies.

Both VIENNA and TricValve represent ideal solutions for patients with structural heart disease, particularly congenital heart disease patients and pediatric cases requiring advanced cardiac interventions. As the latest innovations in structural heart intervention, these technologies provide additional treatment options for patients with complex valvular heart conditions, especially those unsuitable for traditional surgical valve replacement procedures.

The systems are optimally indicated for: Severe aortic stenosis cases, Patients with moderate-to-high surgical risk, Elderly patients with multiple comorbidities, Patients unsuitable for conventional open-heart valve replacement surgery. With their designs, VIENNA and TricValve contribute to improved treatment outcomes, shorter recovery time, and enhanced patient quality of life.

During the workshop, HDN and Relisys also conducted hands-on demonstrations using the VIENNA transcatheter aortic valve model and the TricValve transcatheter caval valve system. Mrs. Mili Gangrade and Mr. Avinash answered detailed questions regarding procedural mechanisms, clinical indications, and practical applications of the technologies.

Chương trình khoa học cập nhật công nghệ TAVI tại Bệnh viện 198
Representatives and speakers from Relisys Medical Devices introducing the delivery catheter system used for the VIENNA transcatheter aortic valve.

The scientific workshop generated highly engaging discussions, with cardiologists and experts expressing strong interest and positive feedback, while also sharing expectations for the technologies to be introduced into clinical use in Vietnam later this year.

HDN would like to sincerely thank the Cardiovascular Institute of 19-8 Hospital, respected professors, and physicians for their participation, valuable feedback, and professional contributions throughout the program. We firmly believe these advanced interventional technologies will soon mark a new milestone in the development of cardiovascular intervention in Vietnam. The scientific program series continues - stay tuned for upcoming destinations with HDN and Relisys!